Founded in 2014 and based in Rockville, MD, NeoImmuneTech (NIT) is a clinical-stage T cell-focused biotech company dedicated to the discovery and development of novel immuno-therapeutics. At NIT, we strive to expand the therapeutic horizon in Immuno-Oncology and Infectious Diseasesby greatly reducing the fatality and morbidity of life-threatening and debilitating diseases. Led by our scientific founder, who invented our lead asset NT-I7 (efineptakin alfa), we are science driven and patient focused. We believe that with NT-I7, the only clinical-stage long-acting human IL-7, we can enhance the body’s immune function to address key resistance mechanisms in Immuno-Oncology and deadly infectious diseases. We have a profound belief, rooted in our science, that we have the power to transform patient care with unique assets like NT-I7, and are committed to the pursuit of discovering their full potential in treating various diseases.

NT-I7 : NT-I7 (efineptakin alfa) is a human IL-7 fusion protein that overcomes the key limitations of endogenous IL-7. NT-I7 has an IL-7 domain that directly promotes T cell development and an engineered N-terminus domain that overcomes the structural instability of IL-7 and enables mass production. The HyFc® domain extends the half-life of IL-7, thereby enhancing bioavailability which provides better potency and stability. NeoBase : The heterodimer Fc platform improves structural stability and increases efficacy, thereby enhancing the immune response, for various multi-specific antibodies, including bispecific antibodies. It allows for flexible arrangement of various antigen target sequences, facilitating more efficient and stable antibody development and enabling rapid development of immuno-cancer drugs. This platform technology, aimed to enhance the immune response through improved protein function, will provide novel design and engineering strategies.

Public

Biotech